Comparable outcomes in patients  with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation

Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.

This article discusses the association between two or more complete remissions in patients with refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL) who underwent haploidentical hematopoietic stem cell transplantation (haplo-HSCT) followed by chemotherapy with decreased overall survival. However, the addition of chimeric antigen receptor (CAR) T-cell (CAR-T) therapy prior to transplantation was observed to improve both OS and leukemia-free survival in this group compared to patients who received transplant and chemotherapy alone.